ALB and diabetic kidney disease: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that canagliflozin reduced the risk of composite renal outcomes and lowered urinary albumin-to-creatinine ratio in patients with DKD (92).